David J. Matlin
CIK: 0001251956
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (23 total)
- Sep 16, 2026CLNN
Clene Inc.
Award(A)Direct434.5K shares at avg. $3.28$1.4M - Aug 13, 2026CLNN
Clene Inc.
Award(A)Directstock option
6.2K shares- - May 21, 2026CLNN
Clene Inc.
Award(A)Directstock option
3.7K shares- - May 21, 2026CLNN
Clene Inc.
Award(A)Directstock option
1.5K shares- - May 14, 2026TLSI
TriSalus Life Sciences, Inc.
Award(A)Direct28.2K shares- - May 14, 2026TLSI
TriSalus Life Sciences, Inc.
Award(A)Direct23.1K shares- - Feb 19, 2026CLNN
Clene Inc.
Award(A)Directstock option
5.4K shares- - Jan 13, 2026CLNN
Clene Inc.
Award(A)DirectWarrant (right to buy)
40K shares- - Jan 13, 2026CLNN
Clene Inc.
Award(A)DirectWarrant (right to buy)
93.3K shares- - Jan 13, 2026CLNN
Clene Inc.
Purchase(P)Direct33.3K shares at avg. $6.50$217K - Nov 13, 2025CLNN
Clene Inc.
Award(A)Directstock option
3.7K shares- - Aug 14, 2025CLNN
Clene Inc.
Award(A)Directstock option
7.3K shares- - Jul 31, 2025TLSI
TriSalus Life Sciences, Inc.
Conversion(C)Direct330K shares- - Jun 12, 2025TLSI
TriSalus Life Sciences, Inc.
Award(A)DirectDirector Stock Option (right to buy)
15K shares- - May 22, 2025CLNN
Clene Inc.
Award(A)DirectStock Options (Right to buy)
1.5K shares- - May 22, 2025CLNN
Clene Inc.
Award(A)DirectStock Options (Right to buy)
10.2K shares- - Feb 27, 2025CLNN
Clene Inc.
Award(A)DirectStock Options (Right to buy)
5.6K shares- - Feb 10, 2025TLSI
TriSalus Life Sciences, Inc.
Other(J)DirectSeries A Preferred Stock
89.5K shares- - Jan 2, 2025TLSI
TriSalus Life Sciences, Inc.
Award(A)Direct10K shares- - Dec 6, 2024CLNN
Clene Inc.
Award(A)DirectStock Options (Right to buy)
5.6K shares- - Oct 2, 2024CLNN
Clene Inc.
Award(A)DirectStock Options (Right to buy)
5K shares- - Sep 30, 2024CLNN
Clene Inc.
Award(A)DirectWarrants (Right to buy)
92.3K shares at avg. $0.13- - Sep 30, 2024CLNN
Clene Inc.
Purchase(P)Direct92.3K shares at avg. $4.75$438K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 16, 2026 |  CLNN Clene Inc. | Award(A) | 434,451 | $3.28 | $1,424,999 | Direct |
| Aug 13, 2026 | CLNN Clene Inc. | Award(A) stock option | 6,230 | - | - | Direct |
| May 21, 2026 | CLNN Clene Inc. | Award(A) stock option | 3,659 | - | - | Direct |
| May 21, 2026 | CLNN Clene Inc. | Award(A) stock option | 1,500 | - | - | Direct |
| May 14, 2026 |  TLSI TriSalus Life Sciences, Inc. | Award(A) | 28,201 | - | $0 | Direct |
| May 14, 2026 | TLSI TriSalus Life Sciences, Inc. | Award(A) | 23,065 | - | $0 | Direct |
| Feb 19, 2026 | CLNN Clene Inc. | Award(A) stock option | 5,372 | - | - | Direct |
| Jan 13, 2026 | CLNN Clene Inc. | Award(A) Warrant (right to buy) | 40,000 | - | - | Direct |
| Jan 13, 2026 | CLNN Clene Inc. | Award(A) Warrant (right to buy) | 93,333 | - | - | Direct |
| Jan 13, 2026 | CLNN Clene Inc. | Purchase(P) | 33,333 | $6.50 | $216,665 | Direct |
| Nov 13, 2025 | CLNN Clene Inc. | Award(A) stock option | 3,692 | - | - | Direct |
| Aug 14, 2025 | CLNN Clene Inc. | Award(A) stock option | 7,255 | - | - | Direct |
| Jul 31, 2025 | TLSI TriSalus Life Sciences, Inc. | Conversion(C) | 330,000 | - | $0 | Direct |
| Jun 12, 2025 | TLSI TriSalus Life Sciences, Inc. | Award(A) Director Stock Option (right to buy) | 15,000 | - | - | Direct |
| May 22, 2025 | CLNN Clene Inc. | Award(A) Stock Options (Right to buy) | 1,500 | - | - | Direct |
| May 22, 2025 | CLNN Clene Inc. | Award(A) Stock Options (Right to buy) | 10,209 | - | - | Direct |
| Feb 27, 2025 | CLNN Clene Inc. | Award(A) Stock Options (Right to buy) | 5,628 | - | - | Direct |
| Feb 10, 2025 | TLSI TriSalus Life Sciences, Inc. | Other(J) Series A Preferred Stock | 89,501 | - | - | Direct |
| Jan 2, 2025 | TLSI TriSalus Life Sciences, Inc. | Award(A) | 10,040 | - | $0 | Direct |
| Dec 6, 2024 | CLNN Clene Inc. | Award(A) Stock Options (Right to buy) | 5,563 | - | - | Direct |
| Oct 2, 2024 | CLNN Clene Inc. | Award(A) Stock Options (Right to buy) | 4,990 | - | - | Direct |
| Sep 30, 2024 | CLNN Clene Inc. | Award(A) Warrants (Right to buy) | 92,307 | $0.13 | - | Direct |
| Sep 30, 2024 | CLNN Clene Inc. | Purchase(P) | 92,307 | $4.75 | $438,458 | Direct |
1-23 of 23 transactions
About MATLIN DAVID J
MATLIN DAVID J (SEC CIK 0001251956) files insider reports with the SEC as Director of Clene Inc. (CLNN) and Director of TriSalus Life Sciences, Inc. (TLSI).
Signal8 holds 17 ownership filings by MATLIN DAVID J, all Form 4s, filed between Oct 2, 2024 and Sep 18, 2026. Those filings report 23 transactions, from Sep 30, 2024 to Sep 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MATLIN DAVID J's filings is in SALT LAKE CITY, UT.
Recent filings by MATLIN DAVID J
- Sep 16, 2026: Grant or award of CLNN shares (Form 4, code A).
- Aug 13, 2026: Grant or award of CLNN derivative securities (Form 4, code A).
- May 21, 2026: Grants or awards of CLNN derivative securities (2 lines, Form 4, code A).
- May 14, 2026: Grants or awards of TLSI shares (2 lines, Form 4, code A).
- Feb 19, 2026: Grant or award of CLNN derivative securities (Form 4, code A).
Other insiders filing for Clene Inc. (CLNN)
- Etherington Robert Dee, President & CEO
- Mortenson Mark, Chief Science Officer
- BROWN MORGAN R, Chief Financial Officer
- Mosca Alison, Director
- Kiernan Matthew, Director
- Desai Arjun JJ, Director